Clinical trials: Response Evaluation
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Asthma
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.
- Trial name
- NCT00394654
- Testing
- MEDI-528 9 mg/kg
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- MedImmune LLC
Relapsing Multiple Sclerosis
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.
- Trial name
- NCT01199861
- Testing
- Fingolimod, Seasonal influenza vaccine, Tetanus toxoid vaccine
- Where
- 25 sites in Belgium, Canada and 7 more
- Volunteers
- 138 people
- Sponsor
- Novartis
Gastrointestinal Cancer
Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
This is an open-label, stratified, two arm design. All patients receive same initial standard preoperative chemotherapy and surgical resection.
- Trial name
- GABLE (NCT03515941)
- Testing
- Oxaliplatin, Capecitabine, Leucovorin
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tannaz Armaghany
Alopecia Areata
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
- Trial name
- NCT04784533
- Testing
- CTP-543
- Where
- 39 sites in United States
- Volunteers
- 317 people
- Sponsor
- Concert Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Dentine Hypersensitivity, Dental Pain
Dose Response of a Tubule Occlusion Agent
To evaluate the efficacy of two different concentrations of a tubule occlusion agent - calcium sodium phosphosilicate in treatment of dentine hypersensitivity
- Trial name
- NCT01075256
- Testing
- 5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
LC002 is an experimental therapeutic vaccine designed to boost the immune response of people infected with HIV. The purpose of this study was to determine the safety and tolerability of and immune response to LC002 in…
- Trial name
- NCT00270205
- Testing
- LC002 standard vaccination, LC002 high-dose vaccination
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at…
- Trial name
- NCT05590403
- Testing
- RSVPreF3 OA investigational vaccine
- Volunteers
- 1,544 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bloodstream Infection
Catheter Related - Gram Positive Bloodstream Infections
Primary Objective: -Evaluate the clinical efficacy and safety of Daptomycin given for treatment of catheter-related bloodstream infections (CRBSI) due to gram positive bacteremia in the context of standard of care antimicrobial…
- Trial name
- NCT00467272
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
COPD
A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD.
- Trial name
- NCT00995475
- Testing
- Fluticasone propionate
- Volunteers
- 18 people
- Sponsor
- University of Dundee
SARS-CoV-2 Infection
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19.
- Trial name
- NCT05799495
- Testing
- PF-07817883
- Where
- 53 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Axial Psoratic Arthritis
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal…
- Trial name
- MAXIMISE (NCT02721966)
- Testing
- Secukinumab
- Where
- 94 sites in Belgium, Bulgaria and 16 more
- Volunteers
- 503 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate…
- Trial name
- NCT01661140
- Testing
- Methotrexate (stable dose), Tocilizumab, Methotrexate (tapering dose)
- Where
- 67 sites in United Kingdom
- Volunteers
- 427 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
- Trial name
- NCT05246280
- Testing
- TC99m-tilmanocept
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
This observational study will evaluate the safety, tolerability and efficacy of tocilizumab in participants with moderate to severe RA who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy.
- Trial name
- NCT01362062
- Testing
- Tocilizumab
- Where
- 7 sites in India
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Labor Onset and Length Abnormalities
Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
The study is designed as a randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening…
- Trial name
- NCT04000438
- Testing
- DF01, PL1
- Where
- 7 sites in Finland, Sweden
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Dilafor AB
Rheumatoid Arthritis
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an…
- Trial name
- NCT02305849
- Testing
- Peficitinib, Methotrexate
- Where
- 146 sites in Japan
- Volunteers
- 519 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
This is an open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial…
- Trial name
- REMYKIR (NCT00999830)
- Testing
- IPH2101
- Where
- 9 sites in France
- Volunteers
- 27 people
- Sponsor
- Innate Pharma
Healthy
A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
An endotoxin challenge will be administered to healthy subjects to induce production of inflammatory markers. An investigational drug or placebo will be administered prior to the endotoxin challenge to assess the effect of the…
- Trial name
- POM (NCT01965600)
- Testing
- PF-06282999, LPS
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer